Related Experiment Videos
[Therapy of venous thromboembolism]
1Abteilung für Hämatologie, Medizinische Klinik, Kantonsspital Luzern. walter.wuillemin@KSL.ch
Praxis
|March 10, 2001
Summary
Venous thromboembolism, encompassing deep vein thrombosis and lung embolism, is primarily treated with anticoagulation. Low molecular weight heparin enables outpatient treatment for many patients, simplifying venous thromboembolism management.
Area of Science:
- Vascular Medicine
- Hematology
Context:
- Deep venous thrombosis and lung embolism share pathogenesis, prognosis, and therapy, leading to the unified term "venous thromboembolism" (VTE).
- Current VTE management relies on anticoagulation, typically initiating with heparin (including low molecular weight heparin - LMWH) followed by oral anticoagulants.
Purpose:
- To outline the therapeutic strategies for venous thromboembolism.
- To highlight the suitability of LMWH for outpatient management and discuss adjunctive therapies.
Summary:
- Low molecular weight heparin (LMWH) offers pharmacokinetic advantages, allowing weight-adapted subcutaneous dosing without laboratory monitoring, making it suitable for outpatient VTE treatment in approximately 75% of cases.
- Outpatient treatment for lung embolism is still under investigation. Massive VTE may require thrombolytic agents or surgery.
- Compression stockings can mitigate post-thrombotic syndrome risk after deep venous thrombosis. Patient self-management of oral anticoagulation is also a viable option.
Impact:
- Facilitates efficient outpatient management of VTE, improving patient convenience and potentially reducing healthcare costs.
- Supports the use of LMWH for widespread outpatient treatment, reserving intensive therapies for severe cases.
- Empowers patients through self-management of anticoagulation and recommends preventative measures for post-thrombotic syndrome.